CLAIMS

1. Use of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing hypertension of normal high blood pressure, in an amount effective for the treatment or prevention of hypertension or normal high blood pressure, and in a sustained-release manner, wherein the normal high blood pressure means systolic blood pressure of 130 mmHg or above but less than 140 mmHg and/or a diastolic blood pressure of 85 mmHg or above but less than 90 mmHg.

2. The use according to Claim 1, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with hyperuricemia or gout.

3. The use of according to Claim 1, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with renal dysfunction.

4. Use of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing hypertension of normal high blood pressure, in an amount effective for the treatment or prevention of renal dysfunction, and in a sustained-release manner, wherein the normal high blood pressure means systolic blood pressure of 130 mmHg or above but less than 140 mmHg and/or a diastolic blood pressure of 85 mmHg or above but less than 90 mmHg.

5. The use according to Claim 4, wherein the renal dysfunction is renal dysfunction with hyperuricemia or gout.

6. The use according to Claim 4, wherein the renal dysfunction is renal dysfunction with hypertension or normal high blood pressure.


7. The use according to any one of Claims 4 to 6, wherein the renal dysfunction is diabetic nephropathy, chronic glomerulonephritis, nephrotic syndrome, or IgA nephropathy.

[Name of Document] CLAIMS

[Claim 1]

A sustained-release pharmaceutical composition for treating or preventing hypertension or normal high blood pressure, comprising as an active ingredient a 2-phenylthiazole compound represented by the following formula (I):

[Chemical Formula 1]




(I)

wherein

$R^1$ represents a $C_{1-8}$ alkoxy group, a morpholino group, a 4-methylpiperazin-1-yl group, or a piperidino group;

$R^2$ represents a nitro group or a cyano group;

X represents a carboxyl group or a $C_{2-7}$ alkoxycarbonyl group; and

Y represents a hydrogen atom or a $C_{1-6}$ alkyl group, or a pharmaceutically acceptable salt thereof.

[Claim 2]

The sustained-release pharmaceutical composition according to Claim 1, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with hyperuricemia or gout.

[Claim 3]

The sustained-release pharmaceutical composition according to Claim 1, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with renal dysfunction.

[Claim 4]

A sustained-release pharmaceutical composition for treating or preventing renal dysfunction, comprising as an active ingredient a 2-phenylthiazole compound

represented by the formula (I) or a pharmaceutically acceptable salt thereof.

[Claim 5]

The sustained-release pharmaceutical composition according to Claim 4, wherein the renal dysfunction is renal dysfunction with hyperuricemia or gout.

[Claim 6]

The sustained-release pharmaceutical composition according to Claim 4, wherein the renal dysfunction is renal dysfunction with hypertension or normal high blood pressure.

[Claim 7]

The sustained-release pharmaceutical composition according to Claims 4 to 6, wherein the renal dysfunction is diabetic nephropathy, chronic glomerulonephritis, nephrotic syndrome, or IgA nephropathy.


[Claim 8]

The sustained-release pharmaceutical composition according to Claims 1 to 7, wherein the 2-phenylthiazole compound represented by the formula (I) is 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid or a pharmaceutically acceptable salt thereof.

[Claim 9]

Use of a 2-phenylthiazole compound represented by the following formula I:

[Chemical Formula 2]



(I)

wherein

$R^1$ represents a $C_{1-8}$ alkoxy group, a morpholino group, a 4-methylpiperazin-1-yl group, or a piperidino group;

$R^2$ represents a nitro group or a cyano group;

X represents a carboxyl group or a $C_{2-7}$ alkoxycarbonyl group; and

Y represents a hydrogen atom or a $C_{1-6}$ alkyl group, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing hypertension of normal high blood pressure, in an amount effective for the treatment or prevention of hypertension or normal high blood pressure.

[Claim 10]

The use according to claim 9, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with hyperuricemia or gout.

[Claim 11]

The use according to claim 9, wherein the hypertension or normal high blood pressure is hypertension or normal high blood pressure with renal dysfunction.

[Claim 12]

Use of a 2-phenylthiazole compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing renal dysfunction, in an amount effective for the treatment or prevention of renal dysfunction, and in a sustained-release manner.

[Claim 13]

The use according to Claim 12, wherein the renal dysfuntion is renal dysfunction with hyperuricemia or gout.

[Claim 14]

The use according to Claim 12, wherein the renal dysfunction is renal dysfunction is renal dysfunction with hypertension or normal high blood pressure.

[Claim 15]

The use according to Claims 12 to 14, wherein the renal dysfunction is diabetic nephropathy, chronic glomerulonephritis, nephrotic syndrome, or IgA nephropathy.

[Claim 16]

The use according to Claims 9 to 15, wherein the 2-phenylthiazole compound represented by the formula (I) is 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid or a pharmaceutically acceptable salt thereof.